![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » OSCIENT PHARMACEUTICALS CORPORATION ANNOUNCES RESULTS OF FDA ADVISORY COMMITTEE MEETING FOR FACTIVE TABLETS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
OSCIENT PHARMACEUTICALS CORPORATION ANNOUNCES RESULTS OF FDA ADVISORY COMMITTEE MEETING FOR FACTIVE TABLETS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
Oscient Pharmaceuticals has announced the results of a meeting of the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee. The panel voted on topics related to the Company's pending supplemental New Drug
Application (sNDA) seeking approval for the use of FACTIVE (gemifloxacin mesylate)
tablets in treating acute bacterial sinusitis (ABS).
BioSpace
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct